{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:26:35Z","timestamp":1773890795034,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.urology.2023.11.013","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T16:48:26Z","timestamp":1701708506000},"page":"71-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A Targeted, Personalized Management Strategy in Advanced Penile Squamous Cell Carcinoma"],"prefix":"10.1016","volume":"184","author":[{"given":"Levi C.","family":"Holland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Gerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bailey","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2023.11.013_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2023.11.013_bib2","doi-asserted-by":"crossref","first-page":"78590","DOI":"10.21037\/tau.2017.05.19","article-title":"Updates on the epidemiology and risk factors for penile cancer","volume":"6","author":"Douglawi","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urology.2023.11.013_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00345-008-0288-6","article-title":"Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer","volume":"27","author":"Hughes","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2023.11.013_bib4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.mayocp.2020.06.031","article-title":"Management of advanced penile cancer","volume":"96","author":"Chahoud","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.urology.2023.11.013_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.urolonc.2004.04.031","article-title":"The role of lymphadenectomy in penile cancer","volume":"22","author":"S\u00e1nchez-Ortiz","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2023.11.013_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4103\/aja202188","article-title":"Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence","volume":"24","author":"Yi","year":"2022","journal-title":"Asian J Androl"},{"key":"10.1016\/j.urology.2023.11.013_bib7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bju.12946","article-title":"Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy","volume":"117","author":"Dickstein","year":"2016","journal-title":"BJU Int"},{"issue":"2 Suppl 1","key":"10.1016\/j.urology.2023.11.013_bib8","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.urology.2010.03.082","article-title":"Treatment of visceral, unresectable, or bulky\/unresectable regional metastases of penile cancer","volume":"76","author":"Pettaway","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.11.013_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/JU.0000000000000746","article-title":"Systematic review and meta-analysis-is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma?","volume":"203","author":"Azizi","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.11.013_bib10","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2023.11.013_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.urology.2023.11.013_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.urology.2023.11.013_bib13","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1001\/jamaoncol.2022.4457","article-title":"Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review","volume":"8","author":"Krebs","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2023.11.013_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2023.11.013_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042952301035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042952301035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T14:39:23Z","timestamp":1709649563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009042952301035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":15,"alternative-id":["S009042952301035X"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2023.11.013","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Targeted, Personalized Management Strategy in Advanced Penile Squamous Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2023.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}